Canagliflozin review – safety and efficacy profile in patients with T2DM

References

• Deeks ED Scheen AJ Canagliflozin: A Review in Type 2 Diabetes Drugs 2017 77 14 1577 1592 28836175
   PubMed Web of Science ®Google Scholar
• Plosker GL Canagliflozin: a review of its use in patients with type 2 diabetes mellitus Drugs 2014 74 7 807 824 24831734
   PubMed Web of Science ®Google Scholar
• Takebayashi K Inukai T Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus J Clin Med Res 2017 9 9 745 753 28811850
   PubMedGoogle Scholar
• Szablewski L Glucose transporters in healthy heart and in cardiac disease Int J Cardiol 2017 230 70 75 28034463
   PubMed Web of Science ®Google Scholar
• Mudaliar S Polidori D Zambrowicz B Henry RR Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside Diabetes Care 2015 38 12 2344 2353 26604280
   PubMed Web of Science ®Google Scholar
• Cefalu WT Leiter LA Yoon KH Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 2013 382 9896 941 950 23850055
   PubMed Web of Science ®Google Scholar
• Davis SN Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial Expert Rev Clin Pharmacol 2014 7 1 21 23 24308786
   PubMed Web of Science ®Google Scholar
• Forst T Guthrie R Goldenberg R Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes Metab 2014 16 5 467 477 24528605
   PubMed Web of Science ®Google Scholar
• Wilding JP Charpentier G Hollander P Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 2013 67 12 1267 1282 24118688
   PubMed Web of Science ®Google Scholar
• Stenlöf K Cefalu WT Kim KA Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin 2014 30 2 163 175 24073995
   PubMed Web of Science ®Google Scholar
• Vasilakou D Karagiannis T Athanasiadou E Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 2013 159 4 262 274 24026259
   PubMed Web of Science ®Google Scholar
• Baker WL Smyth LR Riche DM Bourret EM Chamberlin KW White WB Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis J Am Soc Hypertens 2014 8 4 e269 262 275
   Web of Science ®Google Scholar
• Neal B Perkovic V de Zeeuw D Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial Am Heart J 2013 166 2 217 223.e11 23895803
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V Mahaffey KW CANVAS Program Collaborative Group Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 2017 377 7 644 657 28605608
   PubMed Web of Science ®Google Scholar
• Ryan PB Buse JB Schuemie MJ Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D) Diabetes Obes Metab 2018 20 11 2585 2597 29938883
   PubMed Web of Science ®Google Scholar
• Heerspink HJ Desai M Jardine M Balis D Meininger G Perkovic V Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects J Am Soc Nephrol 2017 28 1 368 375 27539604
   PubMed Web of Science ®Google Scholar
• Jardine MJ Mahaffey KW Neal B CREDENCE study investigators The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics Am J Nephrol 2017 46 6 462 472 29253846
   PubMed Web of Science ®Google Scholar
• Flores E Santos-Gallego CG Diaz-Mejía N Badimon JJ Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity? Cardiovasc Drugs Ther 2018 32 2 213 222 29679303
   PubMed Web of Science ®Google Scholar
• Rizzi M Trevisan R Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors Nutr Metab Cardiovasc Dis 2016 26 11 963 970 27514605
   PubMed Web of Science ®Google Scholar
• Singh M Kumar A Risks Associated with SGLT2 Inhibitors: An Overview Curr Drug Saf 2018 13 2 84 91 29485006
   PubMed Web of Science ®Google Scholar
• Xiong W Xiao MY Zhang M Chang F Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials Medicine (Baltimore) 2016 95 48 e5473 27902600
   PubMed Web of Science ®Google Scholar
• Sinclair AJ Bode B Harris S Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis J Am Geriatr Soc 2016 64 3 543 552 27000327
   PubMed Web of Science ®Google Scholar
• Perlman A Heyman SN Matok I Stokar J Muszkat M Szalat A Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database Nutr Metab Cardiovasc Dis 2017 27 12 1108 1113 29174031
   PubMed Web of Science ®Google Scholar
• Peene B Benhalima K Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Ther Adv Endocrinol Metab 2014 5 5 124 136 25419452
   PubMedGoogle Scholar
• Perkovic V Jardine M Vijapurkar U Meininger G Renal effects of canagliflozin in type 2 diabetes mellitus Curr Med Res Opin 2015 31 12 2219 2231 26494163
   PubMed Web of Science ®Google Scholar
• Peters AL Henry RR Thakkar P Tong C Alba M Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes Diabetes Care 2016 39 4 532 538 26989182
   PubMed Web of Science ®Google Scholar
• Alba M Xie J Fung A Desai M The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus Curr Med Res Opin 2016 32 8 1375 1385 27046479
   PubMed Web of Science ®Google Scholar
• Watts NB Bilezikian JP Usiskin K Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus J Clin Endocrinol Metab 2016 101 1 157 166 26580237
   PubMed Web of Science ®Google Scholar
• De Jonghe S Proctor J Vinken P Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin Chem Biol Interact 2014 224 1 12 25289773
   PubMed Web of Science ®Google Scholar
• Lin HW Tseng CH A Review on the Relationship between SGLT2 Inhibitors and Cancer Int J Endocrinol 2014 2014 719578 25254045
   PubMed Web of Science ®Google Scholar
• Tang H Dai Q Shi W Zhai S Song Y Han J SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials Diabetologia 2017 60 10 1862 1872 28725912
   PubMed Web of Science ®Google Scholar
• Bode B Stenlöf K Harris S Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes Diabetes Obes Metab 2015 17 3 294 303 25495720
   PubMed Web of Science ®Google Scholar
• Desai M Yavin Y Balis D Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus Diabetes Obes Metab 2017 19 6 897 900 28083972
   PubMed Web of Science ®Google Scholar
• Erondu N Desai M Ways K Meininger G Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program Diabetes Care 2015 38 9 1680 1686 26203064
   PubMed Web of Science ®Google Scholar